Envestnet Asset Management Inc. Raises Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

Envestnet Asset Management Inc. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 202,846 shares of the company’s stock after purchasing an additional 4,807 shares during the quarter. Envestnet Asset Management Inc. owned 0.20% of Neurocrine Biosciences worth $28,476,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Neurocrine Biosciences by 59.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock valued at $535,659,000 after buying an additional 1,590,749 shares during the last quarter. Norges Bank acquired a new stake in Neurocrine Biosciences in the second quarter valued at $122,278,000. Los Angeles Capital Management LLC boosted its stake in Neurocrine Biosciences by 19,454.9% during the 2nd quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock valued at $93,595,000 after acquiring an additional 740,842 shares during the last quarter. AQR Capital Management LLC grew its holdings in Neurocrine Biosciences by 40.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock worth $189,794,000 after acquiring an additional 435,385 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth about $42,933,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director George J. Morrow sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the transaction, the director owned 7,068 shares in the company, valued at approximately $1,013,339.16. The trade was a 67.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kyle Gano sold 36,400 shares of the firm’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This trade represents a 20.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 61,966 shares of company stock worth $8,625,166. Insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Zacks Research cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Truist Financial decreased their target price on Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Piper Sandler upped their price target on Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research note on Thursday. Finally, Wall Street Zen raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, February 8th. Fifteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $177.56.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

Neurocrine Biosciences Trading Down 10.4%

NBIX opened at $123.10 on Friday. The business’s 50 day moving average is $140.77 and its 200-day moving average is $140.46. The stock has a market cap of $12.27 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $160.18.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.